Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCL2 and JUNB abnormalities in primary cutaneous lymphomas.

X Mao1, G Orchard, D M Lillington

  • 1Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, UK. mxmayo@yahoo.co.uk

The British Journal of Dermatology
|September 21, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro effects of wound-dressings on key wound healing properties of dermal fibroblasts.

Experimental dermatology·2024
Same author

The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort.

The British journal of dermatology·2020
Same author

Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.

The British journal of dermatology·2019
Same author

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.

The British journal of dermatology·2018
Same author

Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016.

Annales de dermatologie et de venereologie·2018
Same author

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

The British journal of dermatology·2018

This study reveals that BCL2 loss and JUNB gain occur in primary cutaneous lymphomas (PCLs), particularly in T-cell lymphomas. These genetic alterations suggest a specific molecular pathway driving certain PCLs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • BCL2 upregulation is common in B-cell lymphomas, promoting anti-apoptotic effects.
  • Loss of BCL2 has been observed in some malignancies, indicating diverse pathogenic mechanisms.

Purpose of the Study:

  • To investigate the genomic and protein expression of BCL2 and JUNB in primary cutaneous lymphomas (PCLs).
  • To compare the expression patterns of BCL2 and JUNB in different types of PCLs.

Main Methods:

  • Analysis of BCL2 and JUNB gene copy number using real-time PCR in 88 PCL samples.
  • Immunohistochemistry (IHC) to assess BCL2 and JUNB protein expression.
  • Fluorescent in situ hybridization (FISH) and gene expression microarray studies for further validation.

Related Experiment Videos

Main Results:

  • BCL2 gene loss was found in 28% of PCL cases, with significant prevalence in Sézary syndrome/mycosis fungoides (SS/MF).
  • JUNB gain was observed in 25% of PCL cases, often co-occurring with BCL2 loss in SS/MF.
  • Absent BCL2 protein expression was frequent in SS/MF and C-ALCL, contrasting with BCL2 expression in PCBCL.

Conclusions:

  • Findings provide a comprehensive view of BCL2 and JUNB status in PCLs.
  • Suggests a selection pressure for BCL2 loss and JUNB upregulation in a subset of cutaneous T-cell lymphomas (CTCLs).
  • Highlights the role of chromosomal deletion and amplification in PCL pathogenesis.